Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P00742
UPID:
FA10_HUMAN
Alternative names:
Stuart factor; Stuart-Prower factor
Alternative UPACC:
P00742; Q14340
Background:
Coagulation factor X, also known as Stuart factor or Stuart-Prower factor, is a vitamin K-dependent glycoprotein crucial in the blood clotting process. It acts by converting prothrombin to thrombin in the presence of factor Va, calcium, and phospholipid, facilitating the transformation of liquid blood into a solid clot.
Therapeutic significance:
Factor X deficiency, a hemorrhagic condition, highlights the protein's critical role in hemostasis. Patients exhibit symptoms ranging from prolonged bleeding to hematuria, underscoring the necessity for targeted therapeutic interventions to manage or correct Factor X-related disorders.